Abstract
Background
Adrenocortical carcinoma (ACC) is a rare and aggressive disease that is often diagnosed at an advanced stage. There is no standard treatment for metastatic ACC; EDP-M (etoposide, doxorubicin, and cisplatin plus mitotane) is one treatment option. A randomized controlled trial (FIRM-ACT) evaluating the efficacy of EDP-M showed progression-free survival (PFS) was 5.0 months, overall survival (OS) was 14.8 months, the response rate was 19%, and adrenal insufficiency occurred in 3.4% of patients. However, the efficacy and safety of this regimen in Asia are not fully reported.
Methods
We retrospectively analyzed 43 patients diagnosed with metastatic ACC at the National Cancer Center Hospital between 1997 and 2020. We evaluated PFS, OS, and response in 17 patients who received EDP-M as first-line therapy.
Results
The median age at treatment initiation was 45 years (range 18–74). Eight patients (47%) had autonomous hormone production, including six patients with hypercortisolism. The best response of partial response and stable disease was seen in two (12%) and ten (59%) patients, respectively. The median PFS was 6.2 months [95% confidence interval (CI): 4.3–10.0]. The median OS was 15.4 months (95% CI 11.6–not reached). Three patients received only one cycle due to adverse effects associated with hypercortisolism. Grade 3/4 adverse events associated with adrenal insufficiency occurred in three (17%) cases, resulting in EDP-M discontinuation.
Conclusions
The EDP-M regimen had similar PFS to that observed in FIRM-ACT. Adrenal insufficiency was more frequent in the current study, but this could be managed with supportive endocrinological care such as cortisol replacement.
Similar content being viewed by others
References
Kebebew E, Reiff E, Duh QY et al (2006) Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 30:872–878. https://doi.org/10.1007/s00268-005-0329-x
Kerkhofs TMA, Verhoeven RHA, Van der Zwan JM et al (2013) Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 49:2579–2586. https://doi.org/10.1016/j.ejca.2013.02.034
Fassnacht M, Dekkers OM, Else T et al (2018) European journal of endocrinology European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Guillaume Assie 10:19. https://doi.org/10.1530/EJE-18-0608
Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189–2197. https://doi.org/10.1056/NEJMoa1200966
Shuayb M, Das A, Uddin MN (2019) Long-term survival in recurrent adrenocortical cancer. BMJ Support Palliat Care 9:47–50. https://doi.org/10.1136/bmjspcare-2018-001568
Ferraù F, Rta Korbonits M (2015) Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol 173:133–157. https://doi.org/10.1530/EJE-15-0354
Sharma ST, Nieman LK, Feelders RA (2015) Comorbidities in Cushing’s disease. Pituitary 18:188–194. https://doi.org/10.1007/s11102-015-0645-6
Li LJ, Chong Q, Wang L et al (2020) Different treatment efficacies and side effects of cytotoxic chemotherapy. J Thorac Dis 12:3785–3795. https://doi.org/10.21037/jtd.2019.08.63
Han HS, Reis IM, Zhao W et al (2011) Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 47(17):2537–2545. https://doi.org/10.1016/j.ejca.2011.06.027
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026
Reimondo G, Puglisi S, Zaggia B et al (2017) Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma. Eur J Endocrinol 177(4):361–367. https://doi.org/10.1530/EJE-17-0452
Daffara F, De Francia S, Reimondo G et al (2008) Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer. https://doi.org/10.1677/ERC-08-0103
Flynn E, Baqar S, Liu D et al (2016) Bowel perforation complicating an ACTH-secreting phaeochromocytoma. Endocrinol Diabetes Metab Case Rep. https://doi.org/10.1530/edm-16-0061
Claps M, Cerri S, Grisanti S et al (2020) Adding metyrapone to chemotherapy plus mitotane for Cushingâ€TMs syndrome due to advanced adrenocortical carcinoma. Endocrine 61:169–172. https://doi.org/10.1007/s12020-017-1428-9
Vanbrabant T, Fassnacht M, Assie G et al (2018) Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis. Eur J Endocrinol 179:429–436
Berruti A, Fassnacht M, Haak H et al (2014) Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol 65:832–838. https://doi.org/10.1016/j.eururo.2013.11.006
Kim Y, Margonis GA, Prescott JD et al (2016) Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma. JAMA Surg 151:365–373. https://doi.org/10.1001/jamasurg.2015.4516
Baudin E, Pellegriti G, Bonnay M et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o, pDDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92(6):1385–1392. https://doi.org/10.1002/1097-0142(20010915)92:6%3c1385::aid-cncr1461%3e3.0.co;2-2
Hermsen IG, Fassnacht M, Terzolo M et al (2011) Plasma concentrations of o, pDDD, o, pDDA, and o, pDDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844–1851. https://doi.org/10.1210/jc.2010-2676 (jcem.endojournals.org)
Mizdrak M, Tičinović Kurir T, Božić J (2021) The role of biomarkers in adrenocortical carcinoma: a review of current evidence and future perspectives. Biomedicines 9:174. https://doi.org/10.3390/biomedicines9020174
Fassnacht M, Berruti A, Baudin E et al (2015) Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol 16:426–435. https://doi.org/10.1016/S1470-2045(15)70081-1
Edgerly M, Velarde M, Wilkerson J et al (2014) The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab 99:1291–1297. https://doi.org/10.1210/jc.2013-2298
Berruti A, Sperone P, Ferrero A et al (2012) Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 166(3):451–458. https://doi.org/10.1530/EJE-11-0918
Le Tourneau C, Hoimes C, Zarwan C et al (2018) Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer 6(1):111. https://doi.org/10.1186/s40425-018-0424-9
Cosentini D, Grisanti S, Dalla Volta A et al (2018) Immunotherapy failure in adrenocortical cancer: where next? Endocr Connect 7(12):E5–E8. https://doi.org/10.1530/EC-18-0398
Ronchi CL, Sbiera S, Kraus L et al (2009) Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 16:907–918. https://doi.org/10.1677/ERC-08-0224
Malandrino P, Al Ghuzlan A, Castaing M et al (2010) Prognostic markers of survival after combined mitotane-and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 17(3):797–807. https://doi.org/10.1677/ERC-09-0341
Roca E, Berruti A, Sbiera S et al (2017) Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer. Endocr Relat Cancer 24(7):319–327. https://doi.org/10.1530/ERC-17-0095
Laufs V, Altieri B, Sbiera S et al (2018) ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. Eur J Endocrinol 178:181–188. https://doi.org/10.1530/EJE-17-0788
Acknowledgements
We wish to thank all of the patients and medical staff who participated in this study.
Funding
No funding was used for the completion of this paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have nothing to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Uchihara, M., Tanioka, M., Kojima, Y. et al. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience. Int J Clin Oncol 26, 2275–2281 (2021). https://doi.org/10.1007/s10147-021-02021-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-021-02021-8